DB04825ApprovedWithdrawnSmall molecule
Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
- Mechanism
- Curator reviewed
Pharmacologically active on Sodium channel protein type 5 subunit alpha, Myosin light chain kinase 2, skeletal/cardiac muscle, and Calmodulin-1
- Formula / weight
- C24H27N · 329.4779 g/mol (avg)
- Code names
- B-436
Resolves to
Clinical / RWD
Structure
InChIKey
IFFPICMESYHZPQ-UHFFFAOYSA-NSMILESCC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Prenylamine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account